Aims: Anti-leucine-rich glioma-inactivated 1 (LGI1) autoimmune encephalitis (AE) is characterized by complex manifestations of seizures. Here, we report a new seizure semiology, attempt to classify the disease by semiology type, and explore the metabolic pattern of each group.
Methods: Anti-LGI1 AE patients were retrospectively screened between May 2014 and September 2019 in our tertiary epilepsy center. All enrolled patients had seizures during long-range video electroencephalogram (EEG) recordings, and all patients (except one) underwent [18 F] fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) scans. Voxel-based metabolic analysis and z-distribution analysis were carried out to determine the metabolic pattern.
Results: Thirty-three patients were enrolled. According to the patients' seizure semiology, we divided the patients into four groups: focal impaired awareness seizures (FIAS, n = 17), faciobrachial dystonic seizures (FBDS)-only (n = 6), FBDS-plus (n = 8), and focal aware motor seizures (FAMS) (n = 2). No significant differences were found in the clinical manifestations or accessory tests except for the onset age (FIAS < FBDS-plus) and seizure semiology. This was the first study to extensively describe the clinical manifestations and EEG of FAMS in anti-LGI1 AE patients. In addition, we found that the patients with different semiologies all showed a wide range of abnormal metabolism, which is not limited to the temporal regions and basal ganglia, and extends far beyond our previous interpretation of FDG-PET data.
Conclusion: Our results showed that FAMS can serve as a rare indicative seizure semiology of anti-LGI1 AE and that individuals with this disease exhibited widespread functional network alterations.
Keywords: FDG-PET; LGI1; autoimmune encephalitis; seizure semiology.
© 2021 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.